Novo Nordisk aims for three new Dicerna drug candidates a year

Novo Nordisk’s ambition with the acquisition of Dicerna is to start three clinical studies a year, says Chief Scientific Officer Marcus Schindler at the company’s capital markets day.


In fall of last year, Danish pharmaceutical firm Novo Nordisk acquired US-based Dicerna for USD 3.3bn. The purchase will bring in several drug candidates annually, says Marcus Schindler, chief scientific officer at Novo Nordisk, at the company’s capital markets day on Thursday.

”The ambition is to initiate an average of three studies a year involving humans,” says Schindler.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs